Investigational therapies for non-muscle invasive bladder cancer

By Smaldone Marc C   Casella Daniel P   Welchons Daniel R   Gingrich Jeffrey R  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 371-383

Informa Healthcare

Access to resources Recommend Favorite

Emerging cell-cycle inhibitors for pancreatic cancer therapy

By Bayraktar Soley  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 571-582

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

By Winquist Eric   Knox Jennifer   Ayoub Jean-Pierre   Wood Lori   Wainman Nancy   Reid Gregory   Pearce Laura   Shah Ajit   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 159-167

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

By Goss G.   Hirte H.   Miller W.   Lorimer I.   Stewart D.   Batist G.   Parolin D.   Hanna P.   Stafford S.   Friedmann J.   Walsh W.   Mathews S.   Douglas L.   Seymour L.  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 147-155

Springer Publishing Company

Access to resources Recommend Favorite

Overactive bladder treatments in early phase clinical trials

By Colli Enrico   Digesu Giuseppe Alessandro   Olivieri Lorenza  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. : 999-1007

Informa Healthcare

Access to resources Recommend Favorite